MNLO - Menlo Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.960
-0.170 (-2.09%)
As of 12:42PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.130
Open8.100
Bid7.950 x 1000
Ask8.000 x 800
Day's Range7.950 - 8.360
52 Week Range6.990 - 39.860
Volume52,612
Avg. Volume205,550
Market Cap182.905M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-4.402
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.50
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    Scott+Scott Attorneys at Law LLP Announces Investigation into Menlo Therapeutics Inc. (MNLO)

    NEW YORK , June 19, 2018 /PRNewswire/ --  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics ...

  • GlobeNewswire5 days ago

    Detailed Research: Economic Perspectives on Verizon Communications, PayPal, Menlo Therapeutics, iClick Interactive Asia Group, BioTime, and Adobe — What Drives Growth in Today's Competitive Landscape

    NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Verizon ...

  • GlobeNewswire19 days ago

    Menlo Therapeutics to Present at Upcoming Investor Conferences

    The Jefferies and JMP conference presentations will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough. The Company’s clinical development program for serlopitant includes ongoing Phase 2 studies for the treatment of pruritus associated with psoriasis and refractory chronic cough and ongoing and planned Phase 3 studies for the treatment of pruritus associated with prurigo nodularis.

  • GlobeNewswire29 days ago

    Stanford Researchers Presented Results from an Exploratory Study of Serlopitant for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients Indicating Reduction in Itch with Serlopitant Treatment

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today announced that data from an exploratory study of serlopitant for the treatment of chronic itch in epidermolysis bullosa (EB) patients was presented by a research team from Stanford University in an oral presentation at the International Investigative Dermatology meeting on May 18, 2018 in Orlando, Florida.

  • GlobeNewswirelast month

    Menlo Therapeutics Reports First Quarter 2018 Financial Results

    “We continue to make progress on the serlopitant clinical development program. In January, Menlo successfully completed an initial public offering (IPO) of 8,050,000 shares of common stock at a public offering price of $17.00 per share, which included the exercise in full by the underwriters of their overallotment option.

  • GlobeNewswirelast month

    Menlo Therapeutics Announces Senior Clinical Leadership Updates

    REDWOOD CITY, Calif., May 07, 2018-- Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying ...

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Menlo Therapeutics, Potbelly, Maximus, Veeva, RLJ Lodging Trust, and Net Element — What Drives Growth in Today's Competitive Landscape

    NEW YORK, April 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Market Exclusive2 months ago

    Here’s What Happened Last Week In Biotech

    It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals and Menlo Therapeutics

    NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Negative news about Acadia's Nuplazid drug being a suspect in many adverse event related deaths had Wall Street on edge yesterday, sending shares of the biotech ...

  • Market Exclusive2 months ago

    Is Menlo Therapeutics A Discount Opportunity At Current Pricing?

    Menlo Therapeutics Inc.(NASDAQ:MNLO) is an early week mover in the biotechnology space this week with the company picking up some volatility on the back of a data-related release. Specifically, and on Monday, Menlo reported some numbers from a phase 2 trial of one of lead development assets and, on the back of the release, has […] The post Is Menlo Therapeutics A Discount Opportunity At Current Pricing? appeared first on Market Exclusive.

  • In fresh IPO's 77 percent fall, another warning sign for biotech investors
    American City Business Journals2 months ago

    In fresh IPO's 77 percent fall, another warning sign for biotech investors

    Ten weeks into its IPO, Menlo Therapeutics was one of the best-performing offerings, soaring more than 100 percent. On news that its drug flunked a mid-stage trial, the stock fell big.

  • GlobeNewswire2 months ago

    Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis

    REDWOOD CITY, Calif., April 08, 2018-- Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying ...

  • Peninsula anti-aging drug company files for $85M IPO
    American City Business Journals2 months ago

    Peninsula anti-aging drug company files for $85M IPO

    This Brisbane company is one of the fastest-growing companies in the anti-aging space, focusing on cellular senescence.

  • 5 Best Stocks That IPO’d in Q1
    InvestorPlace2 months ago

    5 Best Stocks That IPO’d in Q1

    The markets may be volatile – but this hasn’t stopped IPOs. According to Renaissance Capital, the first quarter saw the largest amount raised by newly public companies since 2014. In all, 43 companies raised a hefty $15.6 billion.

  • These are the companies in Bay Area IPO pipeline expected to go public this year if market choppiness doesn't derail them
    American City Business Journals3 months ago

    These are the companies in Bay Area IPO pipeline expected to go public this year if market choppiness doesn't derail them

    Here's a look at who may go public in the Bay Area after three IPOs from the region were the best performing in the country in the first quarter.

  • GlobeNewswire3 months ago

    Menlo Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

    REDWOOD CITY, Calif., March 28, 2018-- Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant, for the treatment of pruritus associated with various underlying ...

  • American City Business Journals3 months ago

    Cancer-fighting East Bay company upsizes IPO, raises $120 million

    An East Bay biotech company, attempting to find next-generation ways to stimulate the immune system to fight cancer, raised $120 million in an upsized initial public offering. The IPO from Hayward's Arcus Biosciences Inc. (RCUS) priced at $15 — at the high end of the company's range — as it increased the number of shares available from 7.1 million to 8 million. It is the third IPO among Bay Area life sciences companies this year.

  • American City Business Journals3 months ago

    Two Bay Area IPOs expected this week as a much bigger one gets closer

    A pair of IPOs from Bay Area companies are expected at the end of the week from Zscaler Inc. and Arcus Biosciences Inc. The one from San Jose-based cloud security company Zscaler is expected Friday and would be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) went public. The offering from Arcus Biosciences is the third from a Bay Area biotech, following two at the end of January from Redwood City companies ARMO Biosciences Inc. (ARMO) and Menlo Therapeutics Inc. (MNLO).

  • American City Business Journals3 months ago

    Zscaler boosts targets by 50 percent ahead of Friday's IPO

    The targets have been raised again for what's expected to be the first Bay Area tech IPO in four months. San Jose-based Zscaler Inc. increased the amount of stock for sale and the price targets on its offer, boosting how much it could raise to about $207 million, up 50 percent. It was valued by private investors at a little over $1 billion when it raised its last venture round in the summer of 2015.

  • Two Bay Area IPOs expected this week as a much bigger one gets closer
    American City Business Journals3 months ago

    Two Bay Area IPOs expected this week as a much bigger one gets closer

    Friday's offering from San Jose-based cloud security company Zscaler is set to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix went public.

  • American City Business Journals3 months ago

    Zscaler boosts targets on what's shaping up as Bay Area's first tech IPO of 2018

    Cloud security unicorn Zscaler Inc. set a price range for its upcoming IPO that would raise up to about $138 million and boost its valuation by about 40 percent. The San Jose company would be valued at around $1.4 billion at the high end of its proposed price range of between $10 and $12 a share. It's in line to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) raised $120 million.

  • American City Business Journals4 months ago

    Cloud security unicorn seeks $100M in Bay Area's likely first tech IPO of year

    Cloud security unicorn Zscaler Inc. is the most likely candidate to end the Bay Area's latest tech IPO drought. There were only six tech IPOs from the region last year that raised more than $100 million. Uncertainties over the massive tax overhaul and disappointing Wall Street debuts from technology unicorns Snap and Blue Apron were blamed for keeping Valley IPOs down last year, along with IPO-sized late stage funding rounds from investors like Softbank.

  • American City Business Journals5 months ago

    Palo Alto creator of software for CFOs may be ready to go public this year

    CFO software developer Adaptive Insights Inc. is reportedly lining up an IPO. The Palo Alto-based business has hired Morgan Stanley to lead the offering, Reuters said it was told by unnamed sources. Adaptive Insights was launched by Robert Hull in 2003 to build a cloud-based software platform that chief financial officers can use for budgeting, forecasting, reporting, consolidation, dashboards and analytics aimed at finance, sales and other business enterprises.

  • Forbes5 months ago

    Nasdaq Exec 'Even More Bullish' On Biotech IPOs As New Entries Soar

    The potential for mergers and acquisitions in biopharma—driven by the new business-friendly tax package—is fueling investor enthusiasm for biotech IPOs.